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ABSTRACT
Neoantigens represent promising targets for personalized cancer vaccine strategies. However, the
feasibility of this approach in lower mutational burden tumors like glioblastoma (GBM) remains
unknown. We have previously reported the use of an immunogenomics pipeline to identify candidate
neoantigens in preclinical models of GBM. Here, we report the application of the same immunoge-
nomics pipeline to identify candidate neoantigens and guide screening for neoantigen-specific T cell
responses in a patient with GBM treated with a personalized synthetic long peptide vaccine following
autologous tumor lysate DC vaccination. Following vaccination, reactivity to three HLA class I- and five
HLA class II-restricted candidate neoantigens were detected by IFN-γ ELISPOT in peripheral blood.
A similar pattern of reactivity was observed among isolated post-treatment tumor-infiltrating lympho-
cytes. Genomic analysis of pre- and post-treatment GBM reflected clonal remodeling. These data
demonstrate the feasibility and translational potential of a therapeutic neoantigen-based vaccine
approach in patients with primary CNS tumors.
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Introduction
Cancer immunogenomics incorporates next-generation sequen-
cing and bioinformatics to predict which tumor-specific somatic
alterations may produce candidate neoantigens that could bind
with high affinity to host MHC molecules and potentially be
recognized by the anti-tumor immune response.1 Due to their
tumor-restricted expression, neoantigens represent compelling
targets for personalized cancer vaccines.2–7 In preclinical tumor
models, polyvalent neoantigen vaccines can be therapeutically
effective.8,9 Furthermore, neoantigen-based vaccines can elicit
immune responses in patients,2,6,7 although these studies have
been restricted to melanoma, which generally possesses high
mutational burdens, and therefore, potentially contains a high
number of candidate neoantigens. Thus, it remains unclear
whether targeting neoantigens is feasible in cancers with lower
mutational burdens.
We have previously reported the successful use of an immu-
nogenomics pipeline to identify candidate neoantigens in two
preclinical mouse models of glioblastoma.10 We used IFN-γ
ELISPOT and neoantigen-specific tetramer assays to identify
the presence of neoantigen-specific T cell responses in two
orthotopic transplantable models. These data support the
hypothesis that CNS immunosurveillance is operational and
capable of inducing an endogenous neoantigen-specific T cell
response against intracranial tumors. However, given that these
preclinical models harbor a carcinogen-induced highmutational
burden not typically seen in patients with glioblastoma, it is
unclear if a similar immunogenomics-based neoantigen discov-
ery platform will translate clinically. Notably, a recent report
demonstrated the generation of neoantigen-specific T cell
responses following an autologous tumor lysate-dendritic cell
vaccine in patients with ovarian carcinoma, a tumor with com-
parable tumor mutational load as glioblastoma.11,12
Here, we report a patientwith glioblastoma (GBM) treatedwith
a heterologous personalized vaccine, including an autologous
tumor lysate-dendritic cell vaccine (DCVax) followed by
a neoantigen-based synthetic long peptide vaccine (GBM.PVax).
Analysis of post-treatment peripheral blood demonstrated detect-
able neoantigen-specific CD8+ and CD4+ T cell responses after
peptide vaccination. Similar responses were observed in post-
treatment tumor-infiltrating lymphocytes (TIL). Furthermore,
genomic and transcriptomic characterization of the mutational
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landscape and tumor microenvironment pre- and post-treatment
demonstrated tumor clonal evolution and evidence of potential
immune evasion. Together, these results support the evaluation of
immunogenomics-based vaccine strategies in glioblastoma and
other tumors exhibiting moderate mutational loads.
Results
Case report
A 66-year-old previously healthy female presented with new-
onset seizures, and a diagnostic brain MRI revealed a right
parietal contrast-enhancing lesion. A near gross total resection
was performed (>99% extent), and pathology revealed GBM
with an unmethylated O6-methylguanine-DNA methyltransfer-
ase (MGMT) promoter, presence of mutated TERT promoter
(C228T), and absence of IDH1/2 mutations – molecular fea-
tures associated with chemotherapy resistance and decreased
overall survival.13-15
Prior to surgery, the patient had consented to an autolo-
gous tumor lysate-dendritic cell vaccine study (DCVax-L)
(NCT00045968) and an institutional personalized neoantigen-
based peptide vaccine study (GBM.PVax) (NCT02510950).
Therefore, following 6 weeks of standard adjuvant radiation
therapy and concurrent temozolomide chemotherapy
(CCRT), the patient received DCVax-L plus temozolomide
during GBM.PVax preparation (Figure 1). DCVax-L was
administered off-trial due to radiographic pseudoprogression
noted following CCRT (data not shown). After cycle 4 of
DCVax-L, GBM.PVax manufacturing was complete so
DCVax-L was discontinued and GBM.PVax was initiated.
To design GBM.PVax, DNA whole exome sequencing
of the resected tumor revealed 52 somatic, missense
mutations (Figure 2(a), Supplementary File). High-
affinity (ic50 <500 nM) candidate neoantigens were iden-
tified using the neoantigen discovery pipeline, pVAC-Seq,
as well as the NetMHCIIpan 3.2 and NetMHCII 2.3
algorithms,10,16 revealing 2 HLA class I-restricted candi-
dates, 32 HLA class II-restricted candidates, and 14 can-
didates with high affinity to both HLA class I and II
alleles (Figure 2(a)). Eight synthetic long peptides (SLPs)
encompassing seven neoantigens were successfully synthe-
sized for inclusion into GBM.PVax (Figure 2(b)).
After cycle 1 of GBM.PVax, the patient developed confu-
sion, and a brain MRI revealed increased T2/FLAIR indicative
of edema/inflammation along with increased size of the T1
contrast-enhancing lesion most consistent with pseudopro-
gression (Figure 2(c)). Symptoms resolved completely with
a short steroid taper, and a repeat brain MRI 4 weeks later
showed a reduction in T2/FLAIR with stabilization of the T1
contrast-enhancing lesion (Figure 2(c)) coinciding with
a significantly improved functional status. The patient con-
tinued to do well clinically through cycles 3 and 4 of GBM.
PVax and noted interval development of axillary lymphade-
nopathy. Unfortunately, the subsequent brain MRI was con-
cerning for disease progression (Figure 2(c)), and a repeat
craniotomy with subtotal resection was performed.
Histopathology demonstrated extensive treatment effect with
only focal areas of residual glioma, and no overt tumor
recurrence indicating the changes on the MRI was again due
to pseudoprogression (Figure 2(d)). The post-surgical course
was complicated by a saddle pulmonary embolus treated with
embolectomy; intraparenchymal hemorrhage plus gastroin-
testinal bleeding from anticoagulation therapy resulting in
a declining functional status that precluded additional GBM-
related therapy. The patient passed away 21 months after
initial diagnosis (Figure 1).
Immunogenicity of personalized vaccine
To assess for the presence of neoantigen-specific T cells post-
vaccination, we first evaluated the immunogenicity of the known
peptides contained within GBM.PVax as the antigens present in
DCVax-L were undefined. First, reactivity to the predicted
immunodominant minimal epitopes of the GBM.PVax peptides
(Table 1) was determined in PBMC obtained 4 months after
initiation of GBM.PVax using IFN-γ ELISPOT. Isolated post-
vaccination CD8+ T cells reacted to the HLA-B*44:02-restricted
neoantigen, GPR133G126E (mGPR133), while CD4
+ T cells were
reactive to both IL22V72I (mIL22) and PTENR47S (mPTEN)
(Figure 3(a)). An expanded screen of alternative mutation-
containing minimal epitopes did not reveal additional reactivity
to any of the GBM.PVax-containing neoantigens (data not
shown). Reactivity to mGPR133, mIL22, and mPTEN appeared
to bemutation-specific as no T cell reactivity was observed to the
corresponding wild-type epitopes (Figure 3(b)). In order to
determine whether these neoantigen-specific responses were
induced or augmented by vaccination rather than as a result of
prior therapies, reactivity was also measured in a PBMC sample
obtained immediately prior to GBM.PVax but after the comple-
tion of DCVax-L administration. A pre-existing CD8+ T cell
response to mGPR133 was present above background prior to
GBM.PVax but increased after peptide vaccination (Figure 3(c)).
As a control for normal variation over time, CD8+ T cell reac-
tivity toHLA-A*24:02 and B*44:02-restricted CMV antigens was
observed prior to GBM.PVax and was noted to decrease between
Day:0 350 63550 100 150 200 250 300
CCRT 1 2 3 4
TMZ
1 2 3 4
DCVax GBM.PVax
Cycle:
Cycle:
Cycle: 1 2 3 4STR ExpiredSTR
Figure 1. Schematic representation of treatment course. Note: cycle 3 of temozolomide was delayed due to thrombocytopenia, and cycle 4 was given at a reduced
dose (100 mg/m2 down from 150 mg/m2) due to intolerance. Abbreviations: STR = subtotal resection; CCRT = concurrent chemoradiation therapy;
TMZ = temozolomide; DCVax = autologous tumor lysate-dendritic cell vaccine.
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the pre- and post-GBM.PVax time points (Figure 3(c)), suggest-
ing that mGPR133 reactivity was likely boosted as a result of
GBM.PVax immunization. NeithermIL22-specific normPTEN-
specific CD4+ T cell responses were detectable above back-
ground prior to GBM.PVax initiation, suggesting both were
increased to detectable levels after immunization with GBM.
PVax (Figure 3(c)).
Because immunity to neoantigens could also develop sec-
ondary to prior therapies (i.e. surgery, radiation, temozolo-
mide and/or DCVax-L) or epitope spreading following
peptide vaccination, we evaluated reactivity to predicted high-
affinity neoantigen candidates not targeted by GBM.PVax
(Table 1). Interestingly, lower level CD8+ T cell responses
were observed to PDIA3T219S (mPDIA3) and WDR63T690M
(mWDR63), while CD4+ T cell reactivity was noted to
MEGF8P238S (mMEGF8), NUP107R558H (mNUP107), and
NVLI644V (mNVL) in post-vaccination PBMC (Figure 3(d)).
Due to lack of additional pre-GBM.PVax PBMC availability,
further characterization of the induction and kinetics of these
additional neoantigen-specific immune responses was not
possible.
Presence of neoantigen-specific TIL following treatment
Next, the presence of neoantigen-specific responses in TIL
isolated from the second surgical specimen was assessed.
Consistent with PBMC, reactivity to mGPR133, mWDR63,
mIL22, mPTEN, and mNVL was observed above background
among CD8+ or CD4+ TIL, however, only responses to
52
Somatic Missense Mutations
2
HLA class I
Neoantigens
14
HLA class I and II 
Neoantigens
32
HLA class II
Neoantigens
2
Candidates
8
Candidates
5
Candidates
2
Soluble
5
Soluble
0
Soluble
GBM.Pvax Synthetic Long Peptides
Antigen Peptide Sequence
VPS13C I1804T LVPMEHYSLPPVTDKMNIELTQL
KIAA1958 R115W VERYPGRPVKAKLDCNWTRDSCDFSY
GPR133 G126E TQGEQSRPIPSAYEGQVISNGFKV
IL22 V72I AKEASLADNNTDIRLIGEKLFHGVS
DLGAP4 G5S MKGLSDSRPRHLSDSLDPPHE
PTEN R47S GFPAERLEGVYSNNIDDVVRFLDSKHK
RLEGVYSNNIDDVVRFLDSKHKNHYK
CHD2 N123T VRRSNRSRQEPSRFTIKEEASSGSESG
WES
pVAC-Seq
NeoAgs Selected
SLPs Produced
a
b
d
T2 FLAIRT1 + Contrast
C1 GBM.PVax
Day 194
Day 279
Day 337
Day 247
c
C2 GBM.Pvax + Steroids
C3,C4 GBM.Pvax + Steroids
Pre-Treatment Post-Treatment
Figure 2. Design and response of a personalized neoantigen-based peptide vaccine for a patient with glioblastoma. (a) Schematic diagram of GBM.PVax design. Non-
synonymous missense mutations are identified by comparing patient-matched PBMC (normal) and tumor DNA whole exome sequencing, then mutations are filtered
through in silico neoantigen discovery pipelines to identify high-affinity HLA class I and/or class II candidates. Top candidates were selected for peptide synthesis as
long peptides (SLPs). Soluble SLPs are incorporated into GBM.PVax. (b) Table listing the 8 SLPs encompassing 7 neoantigens included in GBM.PVax. The location of
the mutated amino acid is enlarged and bolded. (c) Representative brain MRI axial images at indicated time points during treatment with GBM.PVax. (d)
Representative H&E sections from initial tumor resection (day 0) and post-treatment tumor resection (day 347). Black line denotes 200 microns.
ONCOIMMUNOLOGY e1561106-3
mGPR133, mIL22, and mNVL were significant (Figure 4(a)).
Spatially, immunohistochemistry demonstrated that T cells
were predominantly restricted to the perivascular space,
though infiltration into the pauci-cellular intraparenchymal
region was also observed (Figure 4(b)).
Treatment-related clonal evolution following treatment
To explore the effect of treatment on tumor evolution, the muta-
tional landscape and clonal architecture of the pre- and post-
treatment tumor specimens were characterized by whole exome
DNA sequencing. SciClone analysis revealed loss of two pre-
treatment subclonal populations (clusters 2 and 4) but emergence
of two additional sub-populations (clusters 3 and 5) post-
treatment (Figure 4(c)). T cell reactivity was observed to neoanti-
gens both private to the lost pre-treatment subclones (mGPR133,
mMEGF8, and mNUP107) and shared within the founder clone
(mWDR63,mPDIA3, mIL22, mPTEN, andmNVL) (Figure 4(c)).
Although transcriptional repression of neoantigens has been sug-
gested to facilitate immune escape,17,18 no changes were observed
in transcriptional expression levels among the founder clone
neoantigens between pre- and post-treatment specimens
(Supplementary File). Furthermore, there was no observed
Table 1. Table of minimal epitope sequences of HLA class I and II-restricted
GBM.PVax and non-GBM.PVax neoantigens screened by IFN-γ ELISPOT for T cell
reactivity including corresponding predicted binding affinity (ic50). The location
of the mutated amino acid is enlarged and underlined.
Neoantigen core sequence Iv50 (nM) GBM.PVax
HLA-A*01:01
KIAA1958 R115W WTRDSCDFSY 368 Yes
HLA-A*24:02
ZMYND12 R192H HYHLANDIYF 171 No
HLA-B*44:02
GPR133G126E YEGQVISNGF 260 Yes
HLA-C*05:01
VPS13C I1804T VTDKMNIEL 55 Yes
PTEN R47S YSNNIDDVV 112 Yes
IL22 V72I LADNNTDIR 138 Yes
DLGAP4 G5S LSDSRPRHL 239 Yes
PDIA3 T219S FEDKSVAYT 380 No
MEGF8 P238S LSSPGLLAV 383 No
HLA-C*06:02
WDR3 T690M FYNDIILMV 109 No
CHD2 N123T SRQEPSRFT 230 Yes
HLA-DRB*01:01
MEGF8 P238S AGAFLSSPGLLAVFG 5 No
SIRPB1 T18M LLMMLLLGRLTGVAG 8 No
NVL I644V GLNFVSVKGPELLNM 9 No
NUP107 R558H LILFFHTLGLQTKEE 10 No
IL22 V72I NNTDIRLIGEKLFHG 51 Yes
PTEN R47S GFPAERLEGVYSNNI 192 Yes
VPS13C I1804T PMEHYSLPPVTDKMN 196 Yes
GPR133 G126E PSAYEGQVISNGFV 282 Yes
CHD2 N123T SNRSRQEPSRFTIKE 325 Yes
*
*
**
*
b
c d
*
CD8+ PBMC
* *
CD4+ PBMC
*
*
p = 0.078
a
CD8+ PBMC CD4+ PBMC
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Figure 3. Immunogenicity of GBM.PVax in peripheral blood. (a-d) Bar graphs from IFN-γ ELISPOT data of positively selected CD8+ (left column) and CD4+ (right
column) PBMC stimulated with indicated peptide. Media = negative control (no peptide). (a) Reactivity screen to GBM.PVax neoantigens. (b) Comparison of reactivity
between mutated and wild-type GBM.PVax neoantigens that demonstrated positive reactivity in Figure 3(a). (c) Comparison of reactivity between pre- and post-GBM.
PVax PBMC. (d) Reactivity screen of non-GBM.PVax neoantigens from Table 1. A, b, and d represent a minimum of two independent experiments done in duplicate.
(c) represents a single experiment done in duplicate due to limited sample. (*) represents p < 0.05 compared to negative control unless otherwise indicated.
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transcriptional repression or loss of heterozygosity of HLA loci
(Supplementary File and data not shown).
In the post-treatment tumor, 7 of the 25 private mutations
were predicted to generate at least one high-affinity HLA class
I-restricted neoantigen, a similar frequency (28%) to the
shared founder clone (33.3%) and private pre-treatment sub-
clones (23%) (Figure 4(d)) suggesting equivalent somatic
mutation and neoantigen rates within the sub-populations.
However, while RNA expression was detected for 2 of 3 and
8 of 13 neoantigens in the private pre-treatment subclones
and founder clone, respectively, no private post-treatment
neoantigen RNA expression was detectable (Figure 4(d) and
Supplementary File), suggestive of possible immunoediting.
Immunologic evolution during treatment
To characterize the effects of treatment on the broader
immune microenvironment, we compared pre- and post-
treatment transcriptomes. Analyses revealed increased relative
expression levels for genes associated with both T cell (CD4,
CD8A) subsets (Figure 5(a)). An increase in cytotoxic CD8 T
cell effector function genes (PRF1, GZMA, GZMB) was also
noted to be upregulated (Figure 5(a)). Among the CD4 T
helper lineage, increased expression of the Treg, Th2 and
Th17 lineage-defining transcription factors FOXP3, GATA3,
and RORC, respectively, were upregulated post-treatment,
while the Th1 master regulator transcription factor, T-bet
(TBX21), was downregulated (Figure 5(a)). Consistent with
the decreased expression of TBX21 and increased expression
of FOXP3, IFNG was not found to be expressed in the post-
treatment specimen (data not shown), while IL10 was noted
to be upregulated (Figure 5(a)), respectively. Similarly, several
isoforms of the Th17 effector cytokine, IL-17, were upregu-
lated (IL17B and IL17D) though other isoforms (IL17A,
IL17C, IL17E, IL17F) were not detected (Figure 5(a) and
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Figure 4. Clonal evolution of neoantigens after treatment. (a) Bar graphs from IFN-γ ELISPOT data of positively selected CD8+ (left column) and CD4+ (right column)
ex vivo expanded TIL isolated from the post-GBM.PVax specimen and stimulated with indicated peptide. Media = negative control (no peptide). Graphs represent
a single experiment done in duplicate due to limited sample. (*) represents p < 0.05 compared to negative control. (b) Representative immunohistochemistry
sections of anti-CD3 and anti-CD8 staining in the post-treatment resection specimen. Black arrow identifies perivascular lymphocytes. Black line denotes 200 microns.
(c) SciClone plot of clonal and subclonal populations present in pre- and post-treatment tumor specimens. VAF = variant allele fraction. Cluster 1 = founder clone
mutations. Bolded neoantigens represent those with observed reactivity by ELISPOT. (d) Venn diagrams of missense mutations (left) and predicted high-affinity HLA
class I neoantigens (right) from the pre- and post-treatment tumor specimens. Numbers indicate respective private or shared missense mutations or neoantigens.
Parentheses represent the number of neoantigens with confirmed expression by RNA-seq.
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data not shown). Expression of the Th2 effector cytokine, IL-4
(IL4) was also not detected in either the pre- or post-
treatment specimens (data not shown). Together, these data
demonstrate that treatment with radiation, chemotherapy,
and vaccination resulted in an overall increase in the relative
gene expression profile of cytotoxic CD8 T cells and non-Th1
CD4 T cell subsets, including regulatory T cells, within the
tumor microenvironment.
A similar mixed response was seen among the myeloid
compartment following treatment with a noted increase in
relative expression levels of both M1 (CD68, STAT1) and M2
(CD163, STAT3) macrophages/microglia compared to pre-
treatment,19 (Figure 5(b)). However, there appeared to be an
overall skewing toward a predominant M2 environment with
the noted upregulation of M2-associated genes CSF1R, CD206,
ARG1, and TGFB1, whereas M1-associated genes NOS2 and
IL12A were relatively downregulated. Consistently, a similar
increase of M2 macrophages has been reported in GBM patients
treated with DCVax following standard chemoradiation.20
Next, we compared expression patterns of select co-
stimulatory and co-inhibitory immune checkpoint molecules.
Genes associated with the co-stimulatory molecules OX40 4–
1BB, CD27, and CD70, as well as the co-inhibitory molecules
PD-1, PD-L1, TIM-3, GITR, VISTA, TIGIT, and LAG3 were
broadly upregulated (Figure 5(c)). Of note, other clinically
actionable immune checkpoint targets (i.e. CTLA4, IDO1,
ICOS, and PDL2) were unchanged or downregulated after
treatment (Figure 5(c)) suggesting there was not a global
upregulation of these molecules between specimens.
To provide an integrated overview of treatment-related
changes in the immune landscape, we applied a previously
described gene set enrichment analysis (GSEA) approach21 in
which non-overlapping metagene sets corresponding to func-
tional immune modules – antigen processing/presentation
(MHC), checkpoints (CP), effector cells (EC), and suppressor
cells (SC) – were normalized to 166 TCGA GBM samples. We
then compared GSEA analysis of transcriptomic data before
and after treatment to this reference dataset (Figure 6). This
a b
c d
Figure 5. Immune landscape of the pre- and post-treatment tumor microenvironment. (a-d) Bar graphs demonstrate the relative gene expression level (log2 fold
change) of indicated immune cell subsets (a, b) or immune checkpoint molecules (c, d) derived from bulk RNA-seq. Dotted line indicates +1.5 and −1.5 log2 fold
changes.
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analysis demonstrated that all four modules were compara-
tively downregulated in the pre-treatment sample compared
to the averaged TCGA GBM samples. In contrast, after treat-
ment, all four modules exhibited increases over the averaged
TCGA GBM z-scores, supporting the observation that both
pro-inflammatory and immunoregulatory mechanisms were
upregulated following treatment with radiation, chemother-
apy, DCVax-L, and GBM.PVax.
Discussion
Here, we describe the successful use of an immunogenomics
pipeline to identify candidate neoantigens for incorporation
into a personalized vaccine to treat GBM. Furthermore, the
same immunogenomics pipeline was used to guide screening
for neoantigen-specific T cell reactivity that may have been
generated endogenously, as a result of prior treatment (sur-
gery, radiation, chemotherapy or DCVax-L), or through epi-
tope spreading. In total, we were able to detect reactivity to
three HLA class I- and five HLA class II-restricted neoanti-
gens from PBMC obtained post-treatment. Moreover,
a similar pattern of reactivity was seen in post-treatment
TIL, suggesting that systemically generated responses are cap-
able of homing to and infiltrating CNS tumors. Lack of
adequate pre-vaccination samples restricted our analysis
regarding the kinetics of these responses, but we were able
to demonstrate an augmentation of neoantigen-specific T cell
responses following vaccination. Regardless, these results sup-
port the rationale for targeting neoantigens even in lower
mutational burden tumors like GBM, where the number of
potentially immunogenic candidates is perhaps more limited
than higher mutational tumors, such as melanoma. These
results are further supported by the recent observation that
an autologous tumor lysate-dendritic cell vaccine was shown
to induce neoantigen-specific responses in ovarian cancer,
another lower mutational burden tumor.11,12
These results combined with previously published
reports2,6,7 support the use of an immunogenomics pipeline
to identify candidate neoantigens for personalized vaccines
across multiple tumor types. It will now be necessary to
determine the therapeutic value of neoantigen vaccine on
improving clinical outcomes in patients, particularly in the
setting of the recent phase 3 study showing no difference in
overall survival with the addition of rindopepimut, a peptide
vaccine targeting the neoantigen, EGFRvIII, to standard of
care therapy for newly diagnosed GBM.22 To this end,
ongoing work by our group and others (NCT02149225,
NCT02287428, NCT03223103, NCT03412877) is directed at
evaluating the clinical efficacy of neoantigen-based vaccines
in GBM.
Post-TreatmentPre-Treatment
0-3 -2 -1 1 2 3
0-2 21-1
Sample-wise (averaged) z-score
Weighted z-score
Figure 6. Modified immunophenoscore diagrams derived from Charoentong et al21 for pre-treatment (top) and post-treatment (bottom) specimens. The gene or
gene set comprising each point around the circle is labeled and grouped in corresponding quadrants. Red to blue color scale represent averaged z-score generated
from 166 TCGA GBM samples. Grayscale represents weighted z-score associated with the composite score of each quadrant corresponding to the genes or gene sets
within the quadrant. MHC = Major histocompatibility complex-associated and antigen presentation genes; CP = checkpoint molecules; EC = effector cells;
SC = suppressor cells.
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Although the Rindopepimut vaccine targeting the junc-
tional sequence created by the EGFRvIII variant also repre-
sented a neoantigen targeting approach, there are several
differences between this approach and the cancer immunoge-
nomics approach in this report. First, the EGFRvIII target is
heterogeneously expressed, which could limit the efficacy of
a vaccine directed at a single target due to therapy-induced
immunoediting. However, by using a multi-valent vaccine
platform such as the one described here, one can incorporate
clonal neoantigens as well as neoantigens that may be
expressed by different subclones to enhance the potential of
targeting a greater proportion of tumor cells. Second, while
rindopepimut efficiently generated robust EGFRvIII-specific
humoral responses,22 it has not been shown to induce
a cytotoxic T cell response. Thus, a vaccine approach that
can generate neoantigen-specific cell-mediated immune
responses may be more effective. Third, patients were not
selected for rindopepimut vaccine by MHC haplotype.
Although predictions of neoantigen binding to HLA mole-
cules are imperfect, the consideration of target affinity may
increase the likelihood of effective T cell priming and target
recognition in patients following vaccine treatment.
It is likely that combination immunotherapies will be neces-
sary to increase therapeutic efficacy. Specifically, many perso-
nalized neoantigen vaccine approaches are combining tailored
vaccines with immune modulating agents, such as checkpoint
blockade therapy. Since neither vaccines nor immune check-
point blockade therapy have been shown to improve survival of
patients with GBM as monotherapies,22-24 the combination of
several complementary immune-based strategies may poten-
tially be more effective. For example, the addition of
a vaccine may improve checkpoint blockade therapy by indu-
cing or increasing the number of tumor-specific T cells present
within the tumor microenvironment.8,17,18 Conversely, check-
point blockade therapy may improve the effector function of
vaccine-induced T cells once they home to the immunosup-
pressive tumor microenvironment.25,26 Thus, while immu-
notherapies have yet to translate into improved survival for
patients with GBM, a combinatorial immune-based approach
may lead to better outcomes in the future.
It will also be important to determine the optimal methods
of vaccination to stimulate the most robust and functional
neoantigen-specific responses to the largest number of candi-
dates per patient. For example, in this case, a heterologous
prime-boost personalized vaccine approach of DCVax-L fol-
lowed by synthetic long peptides was administered.
Additional vaccine platforms – including nucleic acids and
viral/bacterial vectors – warrant study. Moreover, identifying
the ideal adjuvant including TLR agonists, immune check-
point agonists/antagonists, or cytokines is an additional vari-
able that has yet to be fully addressed.
Although we recognize the limitations from a single
patient study, further consideration is needed with regard
to monitoring the anti-tumor effects of vaccines in the
CNS. Specifically, it is challenging to determine the efficacy
of immune-based treatments in a tissue site, in this case, the
CNS, in which it is more difficult to sample tissue itera-
tively to understand in situ immune activity. As a proxy for
immune activity at the tumor site, we identified neoantigen-
specific T cell responses in the blood, and we were able to
culture neoantigen-specific TIL from the redo surgery sam-
ple. However, we did not observe a robust T cell infiltrate at
the time of the patient’s second surgery, a finding that was
supported by our gene expression analysis. These findings
raise the possibility that further study is needed to under-
stand the kinetics of T cell homing to the CNS following
vaccination. Additionally, these data underscore the influ-
ence of the large myeloid compartment within the GBM
microenvironment. Further study is necessary to under-
stand how to effectively enhance neoantigen-specific T cell
activity, the effects of vaccines on the microenvironment,
and how these parameters change with combination
treatment.
The presence of pseudoprogression on the post-
vaccination MRI represents another important consideration
for vaccine trials in GBM as well as other novel immunother-
apeutic strategies targeting CNS malignancies such as CAR
T cells.27 Radiographically assessing treatment response may
be difficult as there are currently no criteria that can accu-
rately and reliably delineate immune reactivity or inflamma-
tion from true tumor progression. This has begun to be
addressed in the setting of immune checkpoint blockade
therapy and brain metastases with the development of the
Immunotherapy Response Assessment in Neuro-Oncology
(iRANO).28 However, in order to spare patients unnecessary
surgical procedures or changes in otherwise effective thera-
pies, novel imaging modalities or adjunct non-invasive mon-
itoring assays will be needed.
Lastly, further work is needed to understand the emergence of
resistant subclones post-treatment despite the presence of anti-
gen-specific T cells. Neoantigenic and molecular profiling of the
post-treatment tumor and microenvironment, respectively, may
provide insight into potential immune evasion mechanisms.
Specifically, the lack of expressed immunogenic neoantigens
private to the resistant subclones suggests escape of active immu-
nosurveillance. Conversely, while not observed in this case, it is
plausible to postulate that treatment-induced changes from
radiation and alkylating chemotherapies may lead to the devel-
opment of new candidate neoantigens that could be targeted
iteratively. Furthermore, the concomitant upregulation of
immunoregulatory factors, such as inhibitory checkpoint mole-
cules and suppressive immune cell subsets, supports the ratio-
nale for combining neoantigen-based vaccines with additional
immunomodulatory strategies such as immune checkpoint
blockade and microenvironment modulators6,7 to augment the
potency of these individual strategies.
In summary, the results presented herein provide proof-of-
principle evidence supporting the feasibility of an immuno-
genomics-guided neoantigen discovery platform to design
personalized vaccines in both CNS and lower mutational
burden tumors.
Materials and methods
Informed consent was signed prior to enrollment. All proce-
dures and experiments were performed in accordance with the
Declaration of Helsinki and an Institutional Review Board-
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approved protocol at the Washington University School of
Medicine. This study is NCT02510950 on clinicaltrials.gov.
Whole exome DNA and RNA sequencing
Library construction, sequencing, and variant detection were
performed as described.29 Briefly, normal and tumor exome
libraries were captured using the Nimblegen VCRome kit and
cDNA was prepared with the TruSeq Stranded Total RNA kit.
Each library was sequenced on an Illumina HiSeq2500.
Somatic variants were detected using an ensemble approach
incorporating statistical and heuristic filters. RNA-sequencing
(RNA-seq) data were processed with Tophat v2.0.8 and
Cufflinks v2.1.1 to generate gene expression values.29
HLA class I and II neoantigen predictions, prioritization,
and selection
Clinical HLA typing was performed. HLA alleles, anno-
tated somatic variants, and FPKM-based variant expres-
sion values were used as pVAC-Seq inputs (www.
pvactools.org),16 which queries the IEDB algorithm collec-
tion to predict HLA class I neoantigen binding. Averaged
binding affinities of NetMHCIIpan 3.2 and NetMHCII 2.3
were used for predicting HLA class II antigens. Candidate
neoantigens for GBM.PVax were based on multiple fac-
tors including predicted HLA class I and/or II binding
affinity, RNA-seq expression level, clonality, predicted
peptide solubility, and targeted HLA allele diversification.
Long peptide synthesis and GBM.PVax administration
Fifteen neoantigens were selected for synthetic long peptide pro-
duction. Ultimately, eight peptides targeting seven candidate
neoantigens were soluble and incorporated into GBM.PVax
(Figure 1(b)). GMP grade peptides were produced by CS Bio
(Menlo Park, CA). Three peptide pools containing 2–3 peptides/
poolwere dissolved inDMSOanddiluted to 1mg/peptide inD5W
containing succinate. For vaccination, each peptide pool was co-
administered subcutaneously with 1.5 mg poly-ICLC (Hiltonol;
Oncovir,Washington, DC) into one of four rotating injection sites
(right arm, left arm, right groin, left groin). Vaccinations were
given on days 1, 3, 5, 8, 15, and 22 (±1 day) of cycle one and then
on day 22 of every subsequent 28-day cycle (Figure 1(a)).
Isolation of PBMC and Ex Vivo Expansion of TIL
Heparinized blood was collected by venipuncture prior to GBM.
PVax initiation and by leukapheresis after GBM.PVax cycle 4.
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, PA) den-
sity gradient centrifugation and cryopreserved in 10% DMSO,
20% FBS, and culture media (RPMI-1640, L-glutamine, penicil-
lin/streptomycin, β-mercaptoethanol, sodium bicarbonate,
sodium pyruvate, 10% heat-inactivated FBS).
TIL were isolated by mincing the resected specimen into
1–2 mm chunks and incubating at 37°C in culture media with
2500 U/mL recombinant human IL-2 (EMED Medical
Company, Maryland Heights, MO). Media was changed every
5–7 days. After 3 weeks, lymphocytes were harvested by Percoll
(GE Healthcare Life Sciences) density gradient centrifugation
and cryopreserved. Cells were stored in liquid nitrogen.
IFN-γ ELISPOT assay
CD8+ and CD4+ cells were isolated from PBMC and TIL using
sequential magnetic bead-based positive selection kits
(STEMCELL Technologies, Vancouver, Canada). Approximately
100,000 double-negative autologous PBMC were incubated on
pre-coated human IFN-γ ELISPOT plates (Cellular Technology,
Ltd., Shaker Heights, OH) with 10 μM of indicated peptide
(GenScript, Piscataway, NJ) plus ~400,000 CD8+ or CD4+
PBMC, or ~20,000 CD8+ or CD4+ TIL for 18–20 hours at 37°C.
Plates were analyzed using the C.T.L. ImmunoSpot kit (Cellular
Technology, Ltd., Shaker Heights, OH).
Analysis of clonal evolution and transcriptome
Clonal evolution was analyzed as described previously.29
Briefly, the SciClone algorithm was used to infer clonal
hierarchy,30 and clonEvol was used to reconstruct tumor
phylogeny.31 For gene set enrichment analysis, gene-specific
expression levels from pre- and post-treatment specimens
were z-score normalized across 166 TCGA-GBM patients as
described previously.21 Immunophenogram figures were gen-
erated using the publicly available R code on GitHub (https://
github.com/mui-icbi/Immunophenogram).
Statistical analysis
Intergroup differences in mean number of spots on ELISPOT
were evaluated using a Student’s t-test with p < 0.05 as
statistically significant (GraphPad Prism, San Diego, CA).
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